Serevent Medicaid Study Could Offer Insight Into African-American Risk

A Serevent Medicaid claims study could provide data on ethnic risk differences for respiratory-related severe adverse events with long-acting beta agonist bronchodilators, GlaxoSmithKline said during a July 13 meeting of FDA's Pulmonary-Allergy Drugs Advisory Committee

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet